In the present study, we showed that sustained transdermal delivery of verapamil via CLCMP-based patches could reduce insulin resistance and MAFLD by inhibiting the TXNIP/NLRP3 inflammasome pathway and improving autophagic degradation of protein aggregates. This evidence concerns the gene TXNIP and Insulin resistance.